This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/3/2026
Good morning and welcome to the Amneal Pharmaceuticals third quarter 2026 earnings call. I will now turn the call over to Amneal's head of investor relations, Tony DiMeo.
Good morning and thank you for joining Amneal Pharmaceuticals third quarter 2026 earnings call. Today we issued a press release reporting Q3 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled Cautionary Statements on Forward-Looking Statements in our press release and presentation for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Chintu Patel, co-founders and co-CEOs, Tasos Konidaris, CFO, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag. Thank you, Tony.
Good morning, everyone. Today, Emneal is a stronger, more diversified company than ever before, with a portfolio focused on high-value products designed to drive durable growth. We've expanded across specialty biosimilars and complex products while building the capabilities and capacity to drive these businesses long term. 2026 marks our seventh consecutive year of top and bottom line growth, a track record that stands out in the industry. Our third quarter performance reflects that progress. with revenue of 863 million, up 10%, adjusted EBITDA of 207 million, up 30%, and adjusted EPS of 26 cents, up 53%. The breadth of our portfolio and the depth of our pipeline give us confidence that we are still early in realizing MNU's full potential. Let me highlight the progress across our key growth areas. First, in biosimilars, we closed the Kashif transaction in Q3. MNIL now has the end-to-end capabilities to succeed in biosimilars, R&D, manufacturing, and commercial in-house. Now it is all about execution. From a macro perspective, We have access to a large and growing biosimilar market with approximately 234 billion of U.S. biologic cells losing exclusivity over the next decade. At the same time, streamlined regulatory pathways, new commercial models such as private labels and accelerating market adoption are creating a major inflection point for the U.S. biosimilar industry. Against this backdrop, our portfolio strategy is deliberately differentiated, balancing targeted, lower competition molecules with a select number of broader biologic opportunities. We believe this approach positions MNIL to capture attractive economics and sustain long-term value creation. From M-Neal for M-Neal biosimilars are a natural extension of our purpose, making key medicines more accessible and affordable while building a durable growth platform. Biologics accounts for more than half of U.S. drug spending, yet represents only 5% of total prescriptions, highlighting the significant affordability and access challenge. We believe we can help address that gap and create value for patients. Second, complex genetics remains a core strength with a proven track record of execution. We have an expanding diversified portfolio of high-demand complex therapies, including women's health, transdermal patches, and important new injectable products approvals such as Landreotide, Bromidepsin and Iohexol. Across dosage forms, these are significant opportunities for sustained growth. We have strategically evolved our portfolio toward high value complex products, where our science, manufacturing capabilities and capacity, Reliable supply and customer relationships set us apart. Third, in specialty, our key brands are performing very well. Two years after launch, Trexon for Parkinson's disease continues to gain share. This is being driven by positive patient experience and compelling clinical evidence with more than three additional hours of good on time per day. and many more. Healthcare remains important aspect of our business that provides diversification and access to government and institutional channels for our high-value products, including biosimilars in the future. Fifth, we are advancing our GLP-1 collaboration with Pfizer as construction of our new dedicated GLP-1 manufacturing facilities for both drug substance and drug product remain on track for 2028. Taken together, MNIL has a fundamentally stronger and more diversified growth profile than ever before. With more growth engines, more innovation, and more opportunities ahead, our focus is on the execution. delivering across each of these areas, converting that potential into results. We believe the momentum of 2026 positions us very well for continued high growth in 2027 and beyond. With that, I'll turn it over to Chintu.
You're reading a preview of the AMRX Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing